Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

ANTONIO RIVERO ROMÁN2026-01-292026-01-29201810.1080/17425255.2018.15067652-s2.0-85052052962https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/29480PharmacologyToxicologyPharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis Cresearch article